Abstract
Breast cancer is the most common cause of cancer in women in the United States. Within breast cancer, the “triple‐negative” subtype, which is negative for estrogen receptor and progesterone receptor expression and negative for ERBB2 amplification, is the most deadly and has the fewest targeted therapies. Triple‐negative breast cancer occurs more commonly in young women and in women of African‐American descent.Identification of somatic genome alterations in cancer has led to development of many targeted therapies. To find such alterations in triple‐negative breasst cancer, we and others have performed systematic high‐throughput sequencing of genomes, exomes, and transcriptomes of these cancers. Here, I will discuss results from our studies, including AKT3 translocation in breast cancer, from The Cancer Genome Atlas, and other studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
